Site search
2956 results for '' found
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abn
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abn
/
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to se
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to se
/
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis (NCT0
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis (NCT0
/
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 [GSK6042981] versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors [GIST] after Imat
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 [GSK6042981] versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors [GIST] after Imat
/
Australasian Dermatology Registry (Trial Not Registered)
Australasian Dermatology Registry (Trial Not Registered)
/
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human
/
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 [IDH1]-mutant glioma (NCT05303519)
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 [IDH1]-mutant glioma (NCT05303519)
/
TRANSFORMING EPILEPSY OUTCOMES WITH PERSONALISED DEEP BRAIN STIMULATION AND EXTENDED INTRACRANIAL EVALUATIONS (ACTRN12626000569303)
TRANSFORMING EPILEPSY OUTCOMES WITH PERSONALISED DEEP BRAIN STIMULATION AND EXTENDED INTRACRANIAL EVALUATIONS (ACTRN12626000569303)
/
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
/
Alfred_Health_GP_News_-_June_2026.pdf